Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
সব দামের পরিবর্তন →Save on this medicine
Same active ingredient — pay up to 56% less
These brands contain the same active ingredient (Omeprazole). Strength and form may differ — confirm substitution with your doctor or pharmacist before switching.
ইঙ্গিত ও ব্যবহার
Peptral এর জন্য নির্দেশিত:
ডোজ নির্দেশিকা
শুধুমাত্র নির্দেশিকা তথ্য
প্রদর্শিত ডোজগুলি সরকারি উৎসের সাধারণ নির্দেশিকা। ব্যক্তিগতকৃত ডোজের জন্য সর্বদা আপনার ডাক্তার বা ফার্মাসিস্টের পরামর্শ নিন।
Adults:
Dosage Oral use. For benign gastric and duodenal ulcer, the usual dose is 20 mg once daily, given for 4 weeks in duodenal ulceration and for 8 weeks in gastric ulceration; in severe or recurrent cases the dose may be increased to 40 mg daily. The maintenance dose for recurrent duodenal ulcer is 20 mg once daily, and for prevention of relapse in duodenal ulcer the dose is 10 to 20 mg daily. For NSAID associated duodenal or gastric ulcer, the dose is 20 mg once daily for 4 weeks, continued for a further 4 weeks if not fully healed; 20 mg once daily is also used as prophylaxis in patients with a history of NSAID associated duodenal or gastric ulcers. For gastro esophageal reflux disease, the dose is 20 mg once daily for 4 weeks, continued for a further 4 to 8 weeks if not fully healed; 40 mg once daily has been given for 8 weeks in gastro esophageal reflux disease that is refractory to other treatment, and the maintenance dose is 20 mg once daily. For long term management of acid reflux disease, the dose is 10 to 20 mg daily. For acid related dyspepsia, the dose is 10 to 20 mg once daily for 2 to 4 weeks. For prophylaxis of acid aspiration, 40 mg is given on the preceding evening, then a further 40 mg 2 to 6 hours before surgery. For Zollinger Ellison syndrome (ZES), the initial dose is 60 mg once daily, with a usual range of 20 to 120 mg daily; if the daily dose exceeds 80 mg, it should be given in two divided doses. For Helicobacter pylori eradication in peptic ulcer disease, omeprazole is recommended at a dose of 20 mg twice daily together with antimicrobial agents, using one of the following combinations: amoxicillin 500 mg with metronidazole 400 mg, both three times a day for one week; or clarithromycin 250 mg with metronidazole 400 mg, both twice a day for one week; or amoxicillin 1 g with clarithromycin 500 mg, both twice a day for one week. For paediatric use in severe ulcerating reflux esophagitis in children over 1 year, if body weight is 10 to 20 kg the dose is 10 to 20 mg once daily for 4 to 12 weeks, and if body weight is over 20 kg the dose is 20 to 40 mg once daily for 4 to 12 weeks. Intravenous injection. For prophylaxis of acid aspiration, omeprazole 40 mg is given slowly as an intravenous injection over about 5 minutes, one hour before surgery. For duodenal ulcer, gastric ulcer or reflux oesophagitis in patients for whom oral medication is not suitable, omeprazole 40 mg once daily by IV injection is recommended. For Zollinger Ellison syndrome (ZES), the recommended initial intravenous dose is 60 mg daily; higher daily doses may be needed and should be adjusted individually, and when the daily dose exceeds 60 mg it should be divided and given twice daily.
পার্শ্বপ্রতিক্রিয়া
Omeprol is well tolerated and adverse reactions have generally been mild and reversible. Skin rash, urticaria and pruritus have been reported. Usually resolving after discontinuation of treatment. In addition photosensitivity, bullous eruption, erythema multiforme, angioedema and alopecia have been reported in isolated cases. Diarrhoea and headache have been reported and may be severe enough to require discontinuation of therapy in a small number of patients. In the majority of cases the symptoms resolved after discontinuation of therapy. Other gastrointestinal reactions have included constipation, nausea/vomiting, flatulence and abdominal pain. Dry mouth, stomatitis and candidiasis have been reported as isolated cases. Paraesthesia has been reported. Dizziness, light headedness and feeling faint have been associated with treatment, but all usually resolve on cessation of therapy. Also reported are somnolence, insomnia and vertigo. Reversible mental confusion, agitation, depression and hallucinations have occurred predominantly in severely ill patients. Arthritic and myalgic symptoms have been reported and have usually resolved when therapy is stopped. In isolated cases, the following have been reported: blurred vision, taste disturbance, peripheral oedema, increased sweating, gynaecomastia, leucopenia, thrombocytopenia, agranulocytosis, pancytopenia, anaphylactic shock, malaise, fever, bronchospasm, encephalopathy in patients with pre-existing severe liver disease, hepatitis with or without jaundice, rarely interstitial nephritis and hepatic failure. Increases in liver enzymes have been observed.
সতর্কতা ও নিষেধাজ্ঞা
Warnings & Precautions
Avoid concomitant use of clopidogrel and Omeprol as the pharmacological activity of clopidogrel is reduced if given concomitantly. Observational studies suggest that proton pump inhibitor (PPI) therapy may be associated with an increased risk for osteoporosis- related fractures of the hip, wrist, or spine. Atrophic gastritis has been noted occasionally in gastric corpus biopsies from patients treated long-term with Omeprol. Concomitant use of PPIs with methotrexate may lead to methotrexate toxicities.
নিষেধাজ্ঞা
Omeprazole should not be used in anyone known to be hypersensitive to it. If a gastric ulcer is suspected, malignancy must be ruled out before starting omeprazole, since the drug can ease symptoms and mask an underlying cancer, delaying diagnosis.